Effect of Arginase Inhibition on Ischemia-Reperfusion Injury in Patients with Coronary Artery Disease with and without Diabetes Mellitus
Figure 3
Response to ischemia-reperfusion.
Change in flow-mediated dilatation (FMD) from baseline induced by ischemia-reperfusion in patients with coronary artery disease (CAD) and CAD plus type 2 diabetes mellitus (CAD+DM) given saline or the arginase inhibitor Nω-hydroxy-nor-arginine (nor-NOHA). Data are presented as means and SD; *P<0.05, ***P<0.001.